Apellis pulls its IPO as biotech bears rampage on Wall Street

Editas ($EDIT) and BeiGene ($BGNE) may have made it to Nasdaq, but the IPO window isn't open for everyone. Apellis pulled their attempt at going public. The Kentucky biotech had filed for an $86 million offering last fall, as the market began to unwind. Analysts expect that the bar for completing an IPO of any kind has been raised high in the first half of 2016, as biotech shares in particular have come in for a beating. Story

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.